MitraClip Procedure for Mitral Regurgitation

The MitraClip procedure is a catheter-based repair for a leaking mitral valve, performed through a vein in the groin rather than through open-heart surgery. A small metal clip is guided to the heart and used to pinch together the two leaflets of the mitral valve, reducing the backward flow of blood (mitral regurgitation) that causes breathlessness, fatigue, and heart failure. Inspired by a decades-old surgical stitch technique, the device has become the most widely used transcatheter option for patients who are too sick or too frail for conventional surgery.

What Problem the Procedure Solves

The mitral valve sits between the heart’s left atrium and left ventricle. When it doesn’t close properly, blood leaks backward with every heartbeat. Over time that leak forces the heart to work harder, stretches the chambers, and worsens heart failure. Some people develop mitral regurgitation because the valve’s own tissue degenerates, with leaflets that bulge or flap out of position. Others develop it secondarily, when heart failure or coronary disease dilates the ventricle and pulls the leaflets apart. Both types can be severe enough to warrant intervention.

Open-heart surgery to repair or replace the valve has long been the gold standard, but many patients with significant mitral regurgitation are elderly, have multiple other conditions, or have weakened heart muscle that makes surgery dangerous. The MitraClip was designed specifically for this population. It draws on the Alfieri “edge-to-edge” surgical technique, in which a surgeon sews the middle portions of the two leaflets together to create a double-opening valve that leaks far less.¹

How the Procedure Is Performed

The MitraClip is delivered through a catheter inserted in a large vein in the groin. From there, it travels up to the right atrium of the heart, where the interventional team punctures the wall between the two upper chambers (the interatrial septum) to cross into the left atrium. This transseptal puncture is guided by real-time ultrasound imaging from a probe placed in the esophagus, and it is one of the most technically demanding steps. Three separate ultrasound viewing angles are used to position the puncture site precisely above and behind the mitral valve.²

Once through the septum, the catheter system is steered down toward the mitral valve. The clip is opened, advanced below the leaflets into the left ventricle, then pulled back so that each arm of the clip catches one leaflet. The team checks the result on ultrasound. If the leak hasn’t improved enough, the clip can be reopened and repositioned. If one clip doesn’t produce sufficient reduction, a second or even third clip can be placed alongside it. The whole procedure typically takes one to three hours, and most patients spend just a few days in the hospital afterward.

Who Qualifies

Patient selection is where much of the clinical skill lies. Not every leaking mitral valve is suited to a clip. Imaging teams evaluate the valve’s anatomy in detail before the procedure. For patients whose valve tissue has degenerated and a leaflet flails outward, the gap between the flailing tip and its opposing leaflet should be less than 10 mm, and the width of the flail segment should be under 15 mm. For patients with functional mitral regurgitation caused by a stretched ventricle, the leaflets need to overlap by at least 2 mm and not be pulled too far below the plane of the valve ring. In either case, the valve opening must remain larger than 4 cm² after clipping, or the repair will create a new problem: mitral stenosis, where the valve is too narrow to let blood flow forward efficiently.³

Beyond anatomy, the broader clinical picture matters. A multidisciplinary heart team weighs the patient’s surgical risk, the severity of heart failure symptoms, and whether medications alone have been adequately tried. For older adults in particular, frailty, cognitive function, nutritional status, and social support all factor into whether the procedure is likely to improve quality of life rather than simply adding a hospital stay.⁴

The Evidence From Major Trials

Two landmark studies shaped how the MitraClip is used today. The first, EVEREST II, randomly assigned patients with mitral regurgitation (mostly from degenerative valve disease) to either the MitraClip or open surgery. At five years, the clip was safer in terms of procedure-related complications, but surgery did a better job of eliminating the leak.⁵ An updated meta-analysis confirmed this pattern: residual moderate-to-severe regurgitation was about two and a half times more common in MitraClip patients both at discharge and at five years, and the need for a repeat procedure was substantially higher. Overall survival, however, was statistically similar between the two groups over a mean follow-up of nearly five years.⁶

The second pivotal trial, COAPT, focused specifically on heart failure patients whose mitral regurgitation was functional, meaning their valves were structurally normal but leaking because the heart was too dilated. Adding MitraClip to standard drug therapy cut heart failure hospitalizations nearly in half over two years compared with drugs alone. All-cause death also dropped substantially, from about 46% to 29%. Freedom from device-related complications at one year was above 96%.⁷ A deeper analysis of the same trial showed that MitraClip patients spent roughly two more months alive and out of the hospital during the two-year follow-up period.⁸

A French trial called MITRA-FR tested the MitraClip in a similar heart failure population but found no benefit. The apparent contradiction generated intense debate, and the most likely explanation centers on patient selection: COAPT enrolled patients with more severe valve leakage relative to the size of their ventricle, whereas MITRA-FR included patients whose ventricles were more dilated and whose regurgitation was proportionally less severe.⁹ The practical takeaway is that not every heart failure patient with a leaky valve benefits; the degree of mismatch between the leak and the ventricular enlargement appears to matter a great deal.

Functional Versus Degenerative Mitral Regurgitation

Despite those differences in trial design, a meta-analysis pooling over 2,300 patients found that short-term results after MitraClip are remarkably similar whether the regurgitation is functional or degenerative. The rate of reducing leakage to moderate or less was comparable in both groups (roughly 77%), the 30-day mortality was extremely low in each, and symptom improvement at one month was likewise similar. Functional-regurgitation patients actually had a slightly higher rate of acute procedural success.¹⁰ The differences between the two groups tend to emerge over longer follow-up, where the underlying heart muscle disease in functional regurgitation can drive re-dilation and recurrent leakage.

How Long Does the Repair Last

Durability is one of the most common concerns patients raise. A recent expert overview pooling data from multiple studies found that mitral regurgitation recurrence and the need for reintervention each hovered between 5% and 10% in the months immediately after the procedure and remained relatively stable for the first three years. By five years, recurrence climbed to about 17%, with reintervention needed in roughly 9%.¹¹ Those numbers are not trivial, but they should be weighed against the population receiving the clips: many of these patients were too high-risk for surgery in the first place, and for a meaningful majority, the repair holds well past three years.

What Can Go Wrong

The MitraClip’s safety profile is generally strong, but complications do occur. The most common ones are bleeding at the groin access site, acute kidney injury (sometimes related to contrast dye used during imaging), procedure-induced mitral stenosis from clipping the valve too tightly, and a residual hole in the wall between the upper chambers created by the transseptal puncture.¹² That hole often closes on its own or remains small enough to be clinically meaningless, but in some patients it can allow blood to shunt between the atria.

A more serious complication is single-leaflet detachment, where one arm of the clip loses its grip on a leaflet. This causes an abrupt return of severe regurgitation and often requires urgent intervention. Management is difficult; sometimes an additional clip can be placed to re-secure the leaflet, but many cases end up needing surgical repair.¹³

When Surgery Is Needed After a Failed Clip

If the MitraClip doesn’t work or the repair deteriorates significantly, surgery remains an option, but it becomes more complicated. Proponents of clip therapy have argued that a failed MitraClip should not prevent later surgical repair. In practice, however, surgeons have reported finding severe leaflet injury, torn chordae, and adhesions in the tissue beneath the valve after clip removal. In one surgical series, valve repair was possible in only about 20% of patients who came to the operating room after a failed clip; the rest required a full valve replacement.¹⁴ A separate analysis confirmed that replacement was the most common surgical approach after clip failure.¹⁵ A repeat transcatheter clip procedure is another option and appears safer than surgery, though recurrence rates after a redo clip are higher, ranging from 20% to 40% at one year.¹⁶

The G4 Device and How the Clip Has Evolved

The MitraClip has gone through several generations. The current version, the G4 system, introduced several improvements that address limitations of earlier models. It offers four clip sizes instead of one, including wider clips with a grasping area 50% larger than the original. In early experience, the wide clips were used in over 80% of patients.¹⁷ The G4 also allows each gripper arm to be raised and lowered independently, meaning the operator can catch one leaflet at a time rather than needing to grab both simultaneously. That independent grasping mechanism was used in about half of initial G4 cases. Additionally, the G4 system includes built-in left atrial pressure monitoring, so the team can assess how well the repair is reducing the pressure overload in real time without needing a separate catheter.¹⁸

MitraClip Versus the PASCAL System

The MitraClip is no longer the only transcatheter edge-to-edge repair device. The PASCAL system, made by Edwards Lifesciences, uses a similar clip-and-grasp concept but with broader paddles and a central spacer designed to fill the gap between the leaflets. In a single-center comparison of patients with complex degenerative disease, procedural success was 95.5% with PASCAL versus 87.5% with MitraClip, and a greater proportion of PASCAL patients achieved very low residual regurgitation.¹⁹ However, a larger multicenter propensity-matched study found that both systems achieved equally high technical success (about 98%), with similar rates of residual leakage, 30-day mortality, and one-year outcomes. Device choice did not independently predict results; what mattered was the patient’s baseline surgical risk score.²⁰ A meta-analysis confirmed no significant difference in the degree of regurgitation reduction, procedure time, reintervention rates, or mortality between the two devices, though PASCAL trended toward slightly better residual leak reduction.²¹ For now, the choice between them often comes down to local expertise and the specific anatomy of the valve.

Blood Thinners After the Procedure

There is no universal protocol for anticoagulation after MitraClip placement. A large retrospective study of over 1,300 patients found wide variation in real-world practice: about 22% received a single antiplatelet drug, roughly 21% received an oral anticoagulant plus an antiplatelet, 19% received an anticoagulant alone, 12% received dual antiplatelet therapy, and 21% received no blood-thinning drugs at all.²² Much of this variation reflects the fact that many MitraClip recipients are already on anticoagulants for atrial fibrillation or other conditions. There is no randomized trial definitively establishing which regimen is optimal, so decisions tend to be individualized based on each patient’s bleeding risk and existing medications.

Mitral Annular Calcification

Heavy calcium buildup around the mitral valve ring (mitral annular calcification) has traditionally been considered a barrier to many valve interventions. For surgeons, it makes stitching a new valve or a repair ring into rock-hard tissue extremely difficult. The MitraClip sidesteps that problem because the clip attaches to the leaflet tips, not to the calcified ring. A study comparing 61 patients with moderate or severe calcification to nearly 800 without it found that procedural success was similar, around 92% versus 95%. At one year, leakage control and symptom improvement were comparable, and the rate of cardiac readmissions actually trended lower in the calcification group.²³ This is a meaningful finding because patients with severe annular calcification often have no good surgical options.

Cost and Value

MitraClip devices are expensive. The clip itself and the catheter delivery system carry a high upfront cost, and the procedure requires a specialized hybrid catheterization lab with advanced imaging. For patients with functional mitral regurgitation and heart failure, however, the economic analysis has generally been favorable. Several studies using data from real-world registries and from the COAPT trial have concluded that MitraClip plus standard medical therapy is cost-effective compared with medical therapy alone, largely because the reduction in repeat hospitalizations offsets much of the initial expense.²⁴ A separate real-world analysis of over 380 patients likewise found MitraClip cost-effective at conventional thresholds when compared with medical therapy for moderate-to-severe functional regurgitation.²⁵ The value proposition is strongest in exactly the patients COAPT studied: those with significant secondary mitral regurgitation and heart failure who are not good candidates for surgery.

Sedation Versus General Anesthesia

Most MitraClip procedures have traditionally been performed under general anesthesia, partly because the esophageal ultrasound probe used for guidance is uncomfortable for an awake patient. But a growing number of centers are experimenting with conscious sedation, sometimes using the drug dexmedetomidine, which keeps patients calm and still without fully suppressing their breathing or blood pressure. Early comparative data suggest that conscious sedation may preserve more normal blood flow dynamics during the procedure and improve efficiency, though robust head-to-head evidence is still limited.²⁶ If the sedation approach proves effective in larger studies, it could shorten recovery times and make the procedure accessible to patients who tolerate general anesthesia poorly.

1
PubMed Central. Percutaneous mitral valve repair: The MitraClip device ↩︎
2
PubMed Central. MitraClip step by step; how to simplify the procedure ↩︎
3
EuroIntervention. Mitral valve anatomy: pre-procedural screening and imaging techniques ↩︎
4
PubMed. Durability of Mitral Valve Transcatheter Edge-to-Edge Repair: An Expert Overview ↩︎
5
PubMed. Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II ↩︎
6
PubMed Central. An updated meta-analysis of MitraClip versus surgery for mitral regurgitation ↩︎
7
American College of Cardiology. Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation – COAPT ↩︎
8
PubMed. Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial ↩︎
9
PubMed. MITRA-FR vs. COAPT: lessons from two trials with diametrically opposed results ↩︎
10
PubMed Central. Short-term and 1-year outcomes after MitraClip therapy in functional versus degenerative mitral regurgitation patients: a systematic review and meta-analysis ↩︎
11
PubMed. Durability of Mitral Valve Transcatheter Edge-to-Edge Repair: An Expert Overview ↩︎
12
PubMed Central. Complications Following MitraClip Implantation ↩︎
13
PubMed Central. Management of MitraClip Single-Leaflet Detachment with an Additional Clip and an Amplatzer Vascular Plug ↩︎
14
EuroIntervention. Surgical mitral valve intervention following a failed MitraClip procedure ↩︎
15
PubMed Central. Mitral valve surgery after a failed MitraClip procedure ↩︎
16
PubMed. Durability of Mitral Valve Transcatheter Edge-to-Edge Repair: An Expert Overview ↩︎
17
PubMed. Transcatheter Edge-to-Edge Mitral Valve Repair With the MitraClip G4 System ↩︎
18
PubMed. Initial Experiences with the MitraClip G4: Review of the Novel Device Features ↩︎
19
PubMed Central. PASCAL mitral valve repair system versus MitraClip: comparison of transcatheter edge-to-edge strategies in complex primary mitral regurgitation ↩︎
20
PubMed. Mitral Valve Transcatheter Edge-to-Edge Repair Using MitraClip or PASCAL: A Multicenter Propensity Score-Matched Comparison ↩︎
21
PubMed Central. Meta-analysis of MitraClip and PASCAL for transcatheter mitral edge-to-edge repair ↩︎
22
PubMed Central. Real-world anticoagulatory treatment after percutaneous mitral valve repair using MitraClip: a retrospective, observational study on 1300 patients ↩︎
23
PubMed Central. Transcatheter edge-to-edge mitral valve repair in patients with mitral annulus calcification ↩︎
24
PubMed. Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial ↩︎
25
International Journal of Cardiology. Cost-effectiveness of the MitraClip system versus medical therapy in patients with moderate/severe functional mitral regurgitation ↩︎
26
European Heart Journal – Valvular and Structural Heart Disease. Anaesthetic strategy and functional outcomes during contemporary transcatheter mitral edge-to-edge repair: a matched comparison of dexmedetomidine-based conscious sedation versus general anaesthesia ↩︎